Early study success for targeted radiation:
This article was originally published in Clinica
Executive Summary
NeoRx has reported that its Pretarget technology cured established human lung, colon and breast cancers implanted into mice in a preclinical study. Complete disappearance of tumours and no regrowth after one year occurred in 100% (10/10) of lung cancers, 100% (10/10) of colon cancers and 80% (8/10) of breast cancers. With Pretarget, a targeting antibody and radiation are injected separately and at different times and join at tumour sites where the antibody has pre-localised, said the Seattle, Washington-based company. The study was published in the Proceedings of the National Academy of Sciences (February 15).
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.